|
🐢
|
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
17 auth.
M. Marty,
F. Cognetti,
D. Maraninchi,
R. Snyder,
L. Mauriac,
M. Tubiana‐Hulin,
S. Chan,
D. Grimes,
A. Antón,
A. Lluch,
...
J. Kennedy,
K. O'Byrne,
P. Conte,
Michael F. Green,
C. Ward,
K. Mayne,
J. Extra
|
10 |
2005 |
10
🐢
|
|
🐜
|
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
10 auth.
G. Meyer,
Z. Marjanovic,
J. Valcke,
B. Lorcerie,
Y. Gruel,
P. Solal-Céligny,
...
C. le Maignan,
J. Extra,
P. Cottu,
D. Farge
|
9 |
2002 |
9
🐜
|
|
🐜
|
Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer
18 auth.
E. Charafe-Jauffret,
C. Ginestier,
F. Iovino,
C. Tarpin,
Mark E. Diebel,
B. Esterni,
G. Houvenaeghel,
J. Extra,
F. Bertucci,
J. Jacquemier,
...
L. Xerri,
G. Dontu,
G. Stassi,
Yi Xiao,
S. Barsky,
D. Birnbaum,
P. Viens,
M. Wicha
|
9 |
2009 |
9
🐜
|
|
🐜
|
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
22 auth.
P. Rougier,
R. Bugat,
J. Douillard,
S. Culine,
Etienne Suc,
P. Brunet,
Y. Bécouarn,
M. Ychou,
Michel Marty,
J. Extra,
...
J. Bonneterre,
A. Adenis,
J. Seitz,
G. Ganem,
M. Namer,
Thierry Conroy,
S. Négrier,
Y. Merrouche,
F. Burki,
M. Mousseau,
P. Hérait,
M. Mahjoubi
|
8 |
1997 |
8
🐜
|
|
🐜
|
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.
8 auth.
R. Rouzier,
J. Extra,
J. Klijanienko,
M. Falcou,
B. Asselain,
A. Vincent-Salomon,
...
P. Vielh,
E. Bourstyn
|
8 |
2002 |
8
🐜
|
|
🦁
|
Pharmacokinetics and safety profile of oxaliplatin.
J. Extra,
M. Marty,
S. Brienza,
J. Misset
|
8 |
1998 |
8
🦁
|
|
🐜
|
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
20 auth.
M. Spielmann,
H. Roché,
T. Delozier,
J. Canon,
G. Romieu,
H. Bourgeois,
J. Extra,
D. Serin,
P. Kerbrat,
J. Machiels,
...
A. Lortholary,
H. Orfeuvre,
M. Campone,
A. Hardy-Bessard,
B. Coudert,
M. Maerevoet,
G. Piot,
A. Kramar,
Anne-Laure Martin,
F. Penault-Llorca
|
8 |
2009 |
8
🐜
|
|
🐜
|
A gene expression signature identifies two prognostic subgroups of basal breast cancer
13 auth.
R. Sabatier,
P. Finetti,
N. Cervera,
E. Lambaudie,
B. Esterni,
E. Mamessier,
A. Tallet,
C. Chabannon,
J. Extra,
J. Jacquemier,
...
P. Viens,
D. Birnbaum,
F. Bertucci
|
8 |
2011 |
8
🐜
|
|
🦁
|
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
J. Extra,
F. Rousseau,
R. Bruno,
M. Clavel,
N. Bail,
Michel M. Marty
|
7 |
1993 |
7
🦁
|
|
🦁
|
Phase I study of oxaliplatin in patients with advanced cancer
J. Extra,
M. Espié,
F. Calvo,
C. Fermé,
L. Mignot,
M. Marty
|
7 |
2004 |
7
🦁
|
|
🐜
|
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
12 auth.
Guy G. Chabot,
D. Abigerges,
G. Catimel,
S. Culine,
M. Forni,
J. Extra,
...
M. Mahjoubi,
Patrice Herait,
J. Armand,
R. Bugat,
Michel Clavel,
Michel Marty
|
7 |
1995 |
7
🐜
|
|
🐜
|
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
9 auth.
M. Forni,
R. Bugat,
G. Chabot,
S. Culine,
J. Extra,
A. Gouyette,
...
I. Madelaine,
Michel M. Marty,
A. Mathieu-Boué
|
7 |
1994 |
7
🐜
|
